164 related articles for article (PubMed ID: 34588590)
21. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
Gao L; Zhang W; Zhang J; Liu J; Sun F; Liu H; Hu J; Wang X; Wang X; Su P; Chen S; Qu S; Shi B; Xiong X; Chen W; Dong X; Han B
Cancer Res; 2021 Feb; 81(4):1026-1039. PubMed ID: 33277366
[TBL] [Abstract][Full Text] [Related]
22. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
Stenzl A; Dunshee C; De Giorgi U; Alekseev B; Iguchi T; Szmulewitz RZ; Flaig TW; Tombal B; Morlock R; Ivanescu C; Ramaswamy K; Saad F; Armstrong AJ
Eur Urol; 2020 Oct; 78(4):603-614. PubMed ID: 32336645
[TBL] [Abstract][Full Text] [Related]
23. Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer.
Myers Chen KV; de Groot AE; Mendez SA; Mallin MM; Amend SR; Pienta KJ
Med Oncol; 2023 Aug; 40(10):284. PubMed ID: 37644281
[TBL] [Abstract][Full Text] [Related]
24. Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer.
Fischer S; Clements S; McWilliam A; Green A; Descamps T; Oing C; Gillessen S
Cancer Treat Res Commun; 2020; 25():100256. PubMed ID: 33307509
[TBL] [Abstract][Full Text] [Related]
25. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
26. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
Pal SK; Patel J; He M; Foulk B; Kraft K; Smirnov DA; Twardowski P; Kortylewski M; Bhargava V; Jones JO
Cancer; 2018 Mar; 124(6):1216-1224. PubMed ID: 29266182
[TBL] [Abstract][Full Text] [Related]
27. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
Swami U; Agarwal N
Cancer Treat Res Commun; 2020; 25():100205. PubMed ID: 32822968
[TBL] [Abstract][Full Text] [Related]
28. Immune infiltrates and PD-L1 expression in treatment-naïve acinar prostatic adenocarcinoma: an exploratory analysis.
Hahn E; Liu SK; Vesprini D; Xu B; Downes MR
J Clin Pathol; 2018 Nov; 71(11):1023-1027. PubMed ID: 30257853
[TBL] [Abstract][Full Text] [Related]
29. Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death.
Xiang Z; Sun Y; You B; Zhang M; Huang C; Yu J; You X; Wu D; Chang C
Cell Death Dis; 2021 Jan; 12(1):68. PubMed ID: 33431795
[TBL] [Abstract][Full Text] [Related]
30. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
[TBL] [Abstract][Full Text] [Related]
31. The evolving options in metastatic castration-sensitive prostate cancer.
Hamilou Z
Curr Opin Support Palliat Care; 2020 Sep; 14(3):270-275. PubMed ID: 32701855
[TBL] [Abstract][Full Text] [Related]
32. Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System.
Erb HHH; Oster MA; Gelbrich N; Cammann C; Thomas C; Mustea A; Stope MB
Anticancer Res; 2021 Jul; 41(7):3271-3279. PubMed ID: 34230121
[TBL] [Abstract][Full Text] [Related]
33. Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype.
Boibessot C; Molina O; Lachance G; Tav C; Champagne A; Neveu B; Pelletier JF; Pouliot F; Fradet V; Bilodeau S; Fradet Y; Bergeron A; Toren P
Clin Transl Med; 2022 Jan; 12(1):e581. PubMed ID: 35075795
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
Armstrong AJ; Shore ND; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
J Urol; 2021 May; 205(5):1361-1371. PubMed ID: 33356529
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma.
Koivisto CS; Parrish M; Bonala SB; Ngoi S; Torres A; Gallagher J; Sanchez-Hodge R; Zeinner V; Nahhas GJ; Liu B; Cohn DE; Backes FJ; Goodfellow PJ; Chamberlin HM; Leone G
Neoplasia; 2020 Oct; 22(10):484-496. PubMed ID: 32818842
[TBL] [Abstract][Full Text] [Related]
36. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.
Freedland SJ; De Giorgi U; Gleave M; Rosbrook B; Shen Q; Sugg J; Haas GP; Shore ND
BMJ Open; 2021 Aug; 11(8):e046588. PubMed ID: 34385241
[TBL] [Abstract][Full Text] [Related]
37. Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran C; Ouk S; Clegg NJ; Chen Y; Watson PA; Arora V; Wongvipat J; Smith-Jones PM; Yoo D; Kwon A; Wasielewska T; Welsbie D; Chen CD; Higano CS; Beer TM; Hung DT; Scher HI; Jung ME; Sawyers CL
Science; 2009 May; 324(5928):787-90. PubMed ID: 19359544
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.
McKay RR; Berchuck J; Kwak L; Xie W; Silver R; Bubley GJ; Chang PK; Wagner A; Zhang Z; Kibel AS; Taplin ME
J Urol; 2021 Jun; 205(6):1689-1697. PubMed ID: 33502237
[TBL] [Abstract][Full Text] [Related]
39. Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy.
Shiota M; Ushijima M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Kajioka S; Eto M
Prostate; 2019 Jul; 79(10):1147-1155. PubMed ID: 31077419
[TBL] [Abstract][Full Text] [Related]
40. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
